Movement Disorders

Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, commented on the promising safety of SPN-830 and who may be best suited for treatment with the newly approved therapy. [WATCH TIME: 4 minutes]

Julie Pilitsis, MD, PhD, MBA, chair of neurosurgery at The University of Arizona Tucson, discussed the impact of a newly approved continuous infusion therapy for Parkinson disease.

Phase 1/2 long-term data showed tividenofusp alfa significantly reduced central and peripheral biomarkers to near-normal levels while improving liver volume, hearing thresholds, adaptive behavior, and cognition in most participants.

Neurology News Network. for the week ending February 9, 2025. [WATCH TIME: 4 minutes]

The 32-week study will enroll 15–20 adults aged 18–80 with Parkinson's-related hyposmia, featuring a 24-week treatment period of twice-daily CYR-064 nasal sprays.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 7, 2024.

The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Roaton, Florida, gave clinical insight on the function of a newly approved therapy for Parkinson disease, a common neurodegenerative disorder. [WATCH TIME: 3 minutes]

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Jonathan Rubin, MD, MBA, chief medical officer at Supernus Pharmaceuticals, talked about the recent approval of the company’s subcutaneous infusion therapy SPN-830 for Parkinson disease.

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, discussed SPN-830, the first and only FDA-approved subcutaneous apomorphine infusion device for patients with Parkinson disease. [WATCH TIME: 2 minutes]

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

The movement disorder specialist and director of Integrative Neurosciences at Allegheny Health Network discussed key advancements in the field of neurology for 2025.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Deborah Benzil, MD, FAAS, vice chair of neurosurgery at Cleveland Clinic's Center for Spine Health, shared her extraordinary journey of resilience, from overcoming repeated rejections to becoming a trailblazer for women in neurosurgery, and reflects on the progress made and the challenges that remain.

Jean Hubble, MD, a retired movement disorder specialist and consultant to the PMD Alliance, shares her reflections on National Women Physicians Day, the unique contributions of women in neurology, and the pathways to fostering future leaders in movement disorders care.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Neurology News Network. for the week ending February 2, 2025. [WATCH TIME: 4 minutes]

Recent results from a phase 2 trial of ATH434 revealed its potential in reducing brain iron accumulation and preserving motor function in early-stage multiple system atrophy.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

The neurointensivist and assistant professor of neurology at Boston Medical Center gave insight on a 2024 paper establishing entrustable professional activities for neurocritical care advanced practice providers.